2016 Biometer Shows Strength in Early and Late Stage Deals but Cracks Beneath the Surface -
The 2016 BioMeter showed strength at both ends of the drug-development spectrum, with extremely strong results for ...more
The full-year 2015 BioMeter paints the picture of a strong year for biotechnology, but deeper analysis shows a cautionary trend. The average BioMeter value for the entire year across all transactions reporting up-front...more